CureDuchenne applauds the U.S. Department of Health and Human Services (HHS) for adding Duchenne muscular dystrophy to the Recommended Uniform Screening Panel (RUSP) for newborn screening.
We also extend our congratulations to Parent Project Muscular Dystrophy (PPMD) for leading the nomination and to Muscular Dystrophy Association (MDA), the co-sponsor. Several pilot newborn screening programs—including one supported by CureDuchenne—were instrumental in showing that Duchenne screening can be implemented effectively and that the diagnostic tools are working.
This forward-thinking and evidence-based decision marks a pivotal step as earlier diagnosis offers families a better chance to preserve function, avoid delays, and begin care and treatment when it may be most effective. This milestone comes at a critical time: three Duchenne research programs that received early funding from CureDuchenne are expected to apply for FDA approval in the coming year. As the pipeline of potential treatments grows, identifying individuals as early as possible becomes even more essential.
We’re grateful to the advocates, families, scientists, and clinicians who made this moment possible. As newborn screening moves toward implementation in states, CureDuchenne will continue to support families, clinicians, and partners every step of the way.
The post BREAKING NEWS: U.S. Department of Health and Human Services (HHS) adds Duchenne Muscular Dystrophy to the Recommended Uniform Screening Panel (RUSP) for Newborn Screening appeared first on CureDuchenne.